Genmab A/S (GEN.CO)
-Copenhagen 184.10 
4.70(2.49%) 10:59AM EDT
| Prev Close: | 188.80 |
|---|
| Open: | 186.50 |
|---|
| Bid: | 184.10 |
|---|
| Ask: | 184.90 |
|---|
| 1y Target Est: | 60.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 184.00 - 190.00 |
|---|
| 52wk Range: | 48.00 - 219.50 |
|---|
| Volume: | 127,723 |
|---|
| Avg Vol (3m): | 225,845 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in DKK.
Headlines
- Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody Drug Conjugate Combining HuMax-TAC and PBD WarheadBusiness Wire(Mon, Jun 17)
- Genmab and ADC Therapeutics Enter Co-Development Collaboration for an Antibody-Drug Conjugate Combining HuMax-TAC and PBD WarheadGlobeNewswire(Mon, Jun 17)
- Teprotumumab Restarts Clinical Development in New IndicationGlobeNewswire(Tue, Jun 11)
- Genmab shares tumble after fund sells sharesat Reuters(Tue, Jun 11)
- Genmab Plunges as Investor Sells 5.5% Stake: Copenhagen Moverat Bloomberg(Tue, Jun 11)
- Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) ProgramGlobeNewswire(Fri, May 31)
- BRIEF-Genmab launches U.S.depositary receipt programat Reuters(Fri, May 31)
- Genmab Hits High as Trial Results Ease Risks: Copenhagen Moverat Bloomberg(Thu, May 30)
- GSK melanoma drugs add to tally of U.S. drug approvalsat Reuters(Thu, May 30)
- GSK and Genmab Announce Positive Top-Line Results From Pivotal Study of ARZERRA(R) (ofatumumab) Combined With Chlorambucil in Previously Untreated Chronic Lymphocytic LeukemiaGlobeNewswire(Wed, May 29)
- Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement CaseGlobeNewswire(Fri, May 17)
- Arzerra sales help Genmab turn loss to profitat Reuters(Tue, May 7)
- BRIEF-Genmab revenue rose to 160 mln DKK in Q1at Reuters(Tue, May 7)
- Genmab Announces Financial Results for the First Quarter of 2013GlobeNewswire(Tue, May 7)
- Q1 2013 Genmab A/S Earnings Release - 11:00 am ETCCBN(Tue, May 7)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(Sep-11)
: | N/A |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forGEN.CO.